Fusion glycoprotein F0

Fusion glycoprotein F0

Fusion glycoprotein F0 Molekülinformation

Molecule Name
Respiratory syncytial virus F protein
Molekülalias
Fusion glycoprotein F0
Drug Development Progress
Anzahl der klinischen Arzneimittel5
Anzahl der inverkehr gebrachten Arzneimittel3
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
Protein F,F,Fusion glycoprotein F0
Molekülhintergrund
The two surface glycoproteins of the mumps virus are the hemagglutinin-neuraminidase (HN) and Fusion proteins. These glycoproteins are essential for viral entry to host cells, and the spread of newly formed virions. The mumps fusion protein (F) is a 538-amino acid, class one fusion surface glycoprotein. It is responsible for the membrane fusion of virus and host cell. The un-cleaved protein has three hydrophobic regions: an amino-terminal signal peptide, an amino terminal region of F1 and the carboxyl-terminal membrane domain. This protein starts as a precursor molecule (F0), and is then cleaved into the active protein by the recognition of a R-X-L/R-R motif by a host endoprotease (furin). The F protein contains two disulfide-linked polypeptides (F1 and F2).

Fusion glycoprotein F0 Produktliste

Species
  • Mumps virus(1)
Tag
  • His Tag & Avi Tag(1)
Host
  • HEK293(1)
Conjugate
  • Biotin-labeled(1)
Grade
  • RUO(1)
Low Endotoxin
  • No(1)
MoleculeCat. No.Product NameArtHostStructurePurityActivitySize&PriceAdd to Cart
Fusion glycoprotein F0
Avitag
RSF-M82E3
Biotinylated Mumps virus (strain Miyahara vaccine) (MuV) Fusion glycoprotein F0 Protein, His,Avitag™
Mumps virus
HEK293
SDS-PAGE

$1520.00

200ug
You Have Viewed 1-1 Of 1 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
CPI-RSV-F VaccineBLB-201Phase 2 ClinicalBlue Lake Biotechnology Inc
Respiratory Syncytial Virus Infections
Details
RSV vaccine (Vaxart)Phase 1 ClinicalVaxart Biosciences Inc
Respiratory Syncytial Virus Infections
Details
GR-2102GR2102; GR-2102Phase 1 ClinicalChongqing Genrix Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd
Respiratory Syncytial Virus Infections
Details
Palivizumab biosimilar (mAbxience)MB-05Phase 1 ClinicalMabxience Sa
Details
RSM-01Phase 1 ClinicalBill & Melinda Gates Medical Research Institute
Respiratory Syncytial Virus Infections
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
NirsevimabAnti-RSV-mAb-D25; SP-0232; MEDI-8897; Anti-RSV MAb-YTEApprovedAimm Therapeutics, MedImmune Inc, SanofiBeyfortus, 乐唯初EURespiratory Syncytial Virus InfectionsSanofi Winthrop Industrie SA2022-10-31
Lower Respiratory Tract Infections; Respiratory Syncytial Virus Infections
Details
PalivizumabABT-315; MEDI-493ApprovedAbbvie Inc, Medimmune LlcSynagisUnited StatesRespiratory Syncytial Virus InfectionsSwedish Orphan Biovitrum Ab (Publ)1998-06-19
Bronchiolitis; Bronchopulmonary Dysplasia; Heart Defects, Congenital; Infant, Premature, Diseases; Premature Birth; Respiratory Syncytial Virus Infections
Details
Respiratory syncytial virus immune globulinRSV-IGIVApprovedMedimmuneRespiGamUnited StatesRespiratory Syncytial Virus Infectionsnull1996-01-01
Respiratory Syncytial Virus Infections
Details
Customer Reviews